Seroprevalence of Anti-SARS-CoV-2 Antibodies in Senegal: A National Population-Based Cross-Sectional Survey, between October and November 2020

Talla, Cheikh; Loucoubar, Cheikh; Roka, Jerlie Loko; Barry, Aliou; Ndiaye, Seynabou; Diarra, Maryam; Faye, Oumar; Dia, Moussa; Tall, Adama; Ndiaye, Oumar; Faye, Rokhaya; Mbow, Adji Astou; Diouf, Babacar; Diallo, Jean Pierre; Ndiaye, Mamadou; Woudenberg, Tom; White, Michael T.; Ting, Jim; Diagne, Cheikh Tidiane; Pasi, Omer; Diop, Boly; Sall, Amadou Alpha; Vigan-Womas, Inès; Faye, Ousmane

doi:10.2139/ssrn.3925475

“…As shown in Table 2, among the published data, SARS-CoV-2 seroprevalence estimates obtained mostly during the first year of pandemic ranged from 2.1% in Zambia (6 districts, July 2020) to 34.7% in Kenya (Nairobi, November 2020) [20][21][22][23][24]. Infection to reported cases ratios-which is the ratio of the number of persons with previous infections as detected by seroprevalence studies (seropositive), to the number of COVID-19 cases detected by the surveillance system during the same period-ranged from 21:1 in Ethiopia (Addis Ababa, June-July 2020) to 295:1 in Senegal (National, October-November 2020) [20][21][22][23][24].…”

Section: Dissemination Of Resultsmentioning

confidence: 99%

“…Seroprevalence results provide critical information for decision makers to guide ongoing public health strategies for the prevention and control of COVID-19. They allow for the assessment of the burden of disease (e.g., cumulative incidence and true case-to-fatality ratio), identification of hidden hotspots, quantification of the infection-to-case ratio, and estimation of vaccination coverage [11,[20][21][22][23][24]. When coupled with other surveillance, clinical, and epidemiologic data, data from these surveys can also help distinguish between a) a well-functioning surveillance system capturing most of the cases; b) a real gap in the ability of public health system to identify, diagnose, and report symptomatic cases; and c) a less severe clinical presentation which may lead to limited healthcare-seeking behavior.…”

Section: Discussionmentioning

confidence: 99%

U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020–February 2022

Hamida

¹

,

Charles

²

,

Murrill

³

et al. 2022

PLOS Glob Public Health

0

View full text Add to dashboard Cite

SARS-CoV-2 seroprevalence surveys provide critical information to assess the burden of COVID-19, describe population immunity, and guide public health strategies. Early in the pandemic, most of these surveys were conducted within high-income countries, leaving significant knowledge gaps in low-and middle-income (LMI) countries. To address this gap, the U.S. Centers for Disease Control and Prevention (CDC) is supporting serosurveys internationally. We conducted a descriptive analysis of international serosurveys supported by CDC during May 12, 2020–February 28, 2022, using an internal tracker including data on the type of assistance provided, study design, population surveyed, laboratory testing performed, and status of implementation. Since the beginning of the pandemic, CDC has supported 72 serosurveys (77 serosurvey rounds) in 35 LMI countries by providing technical assistance (TA) on epidemiologic, statistical, and laboratory methods, financial assistance (FA), or both. Among these serosurvey rounds, the majority (61%) received both TA and FA from CDC, 30% received TA only, 3% received only FA, and 5% were part of informal reviews. Fifty-four percent of these serosurveys target the general population, 13% sample pregnant women, 7% sample healthcare workers, 7% sample other special populations (internally displaced persons, patients, students, and people living with HIV), and 18% assess multiple or other populations. These studies are in different stages of implementation, ranging from protocol development to dissemination of results. They are conducted under the leadership of local governments, who have ownership over the data, in collaboration with international partners. Thirty-four surveys rounds have completed data collection. CDC TA and FA of SARS-CoV-2 seroprevalence surveys will enhance the knowledge of the COVID-19 pandemic in almost three dozen LMI countries. Support for these surveys should account for current limitations with interpreting results, focusing efforts on prospective cohorts, identifying, and forecasting disease patterns over time, and helping understand antibody kinetics and correlates of protection.

show abstract

Assessing the Burden of COVID-19 in Developing Countries: Systematic Review, Meta-Analysis, and Public Policy Implications

Owusu‐Boaitey

¹

,

Pugh

²

,

Fosdick

³

et al. 2021

Preprint

View full text Add to dashboard Cite

Introduction The infection fatality rate (IFR) of COVID-19 has been carefully measured and analyzed in high-income countries, whereas there has been no systematic analysis of age-specific seroprevalence or IFR for developing countries. Indeed, it has been suggested that the death rate in developing countries may be far lower than in high-income countries - an outcome that would be starkly different from the typical pattern for many other infectious diseases. Methods We systematically reviewed the literature to identify all serology studies in developing countries that were conducted using representative samples of specimens collected by early 2021. For each of the antibody assays used in these serology studies, we identified data on assay characteristics, including the extent of seroreversion over time. We analyzed the serology data using a Bayesian model that incorporates conventional sampling uncertainty as well as uncertainties about assay sensitivity and specificity. We then calculated IFRs using individual case reports or aggregated public health updates, including age-specific estimates whenever feasible. Results Seroprevalence in many developing country locations was markedly higher than in high-income countries but still far short of herd immunity. In most locations, seroprevalence among older adults was similar to that of younger age-groups. Age-specific IFRs were 1.3-2.5x higher than in high-income countries. The median value of population IFR was 0.5% among developing countries with satisfactory death reporting as of 2016, compared to a median of 0.05% for other developing countries. Conclusion The burden of COVID-19 is far higher in developing countries than in high-income countries, reflecting a combination of elevated transmission to middle-aged and older adults as well as limited access to adequate healthcare. These results underscore the critical need to accelerate the provision of vaccine doses to vulnerable populations in developing countries.

show abstract

U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020–February 2022

Hamida¹,

Charles

²

,

Murrill

³

et al. 2022

Preprint

View full text Add to dashboard Cite

SARS-CoV-2 seroprevalence surveys provide critical information to assess the burden of COVID-19, describe population immunity, and guide public health strategies. Early in the pandemic, most of these surveys were conducted within high-income countries, leaving significant knowledge gaps in low-and middle-income (LMI) countries. To address this gap, the U.S. Centers for Disease Control and Prevention (CDC) is supporting serosurveys internationally. We conducted a descriptive analysis of international serosurveys supported by CDC during May 12, 2020–February 28, 2022, using an internal tracker including data on the type of assistance provided, study design, population surveyed, laboratory testing performed, and status of implementation. Since the beginning of the pandemic, CDC has supported 72 serosurveys (77 serosurvey rounds) in 35 LMI countries by providing technical assistance (TA) on epidemiologic, statistical, and laboratory methods, financial assistance (FA), or both. Among these serosurvey rounds, the majority (61%) received both TA and FA from CDC, 30% received TA only, 3% received only FA, and 5% were part of informal reviews. Fifty-four percent of these serosurveys target the general population, 13% sample pregnant women, 7% sample healthcare workers, 7% sample other special populations (internally displaced persons, patients, students, and people living with HIV), and 18% assess multiple or other populations. These studies are in different stages of implementation, ranging from protocol development to dissemination of results. They are conducted under the leadership of local governments, who have ownership over the data, in collaboration with international partners. Thirty-four surveys rounds have completed data collection. CDC TA and FA of SARS-CoV-2 seroprevalence surveys will enhance the knowledge of the COVID-19 pandemic in almost three dozen LMI countries. Support for these surveys should account for current limitations with interpreting results, focusing efforts on prospective cohorts, identifying, and forecasting disease patterns over time, and helping understand antibody kinetics and correlates of protection.

show abstract

Seroprevalence of Anti-SARS-CoV-2 Antibodies in Senegal: A National Population-Based Cross-Sectional Survey, between October and November 2020

Cited by 3 publications

References 22 publications

U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020–February 2022

U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020–February 2022

Assessing the Burden of COVID-19 in Developing Countries: Systematic Review, Meta-Analysis, and Public Policy Implications

U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020–February 2022

Contact Info

Product

Resources

About